DJIA 17,094.62 -12.08 -0.07%
NASDAQ 4,564.03 -6.61 -0.14%
S&P 500 1,998.11 -1.91 -0.10%
market minute promo

Synageva BioPharma (NASDAQ: GEVA)

77.66 0.69 (0.89%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GEVA $77.66 0.89%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $77.36
Previous Close $76.97
Daily Range $76.23 - $77.77
52-Week Range $44.54 - $119.42
Market Cap $2.6B
P/E Ratio -16.24
Dividend (Yield) $0.00 (0.0%)
Volume 24,344
Average Daily Volume 266,405
Current FY EPS -$6.21

Sector

Healthcare

Industry

Drugs

Synageva BioPharma (GEVA) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of a new class of antiviral drug treatments called fusion inhibitors. Website: http://www.synageva.com/

News & Commentary Rss Feed

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

Synageva Slips on Wider-than-Expected Q2 Loss - Analyst Blog

Thursday's ETF Movers: BSCF, XBI

Sector Update: Health Care

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 1

Sector Update: Health Care Stocks Following Broader Markets Highers; GlycoMimetics Jumps More Than 10% After Naming Cancer-Specialist to Board

3 Stocks Crushed by the Market This Week

No pops and sizzles for these stocks. Just drops and fizzles.

Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

Synageva's Sebelipase Alfa Meets Primary Endpoint in ARISE - Analyst Blog

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across M

Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

GEVA: Insiders Vs. Shorts

See More GEVA News...

GEVA's Top Competitors

GEVA $77.66 (0.89%)
Current stock: GEVA
AMGN $137.53 (0.19%)
Current stock: AMGN
GILD $107.14 (0.82%)
Current stock: GILD
BIIB $339.62 (-0.98%)
Current stock: BIIB